315 related articles for article (PubMed ID: 26479921)
1. Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.
Alam MS; Gaida MM; Bergmann F; Lasitschka F; Giese T; Giese NA; Hackert T; Hinz U; Hussain SP; Kozlov SV; Ashwell JD
Nat Med; 2015 Nov; 21(11):1337-43. PubMed ID: 26479921
[TBL] [Abstract][Full Text] [Related]
2. Counter-regulation of T cell effector function by differentially activated p38.
Alam MS; Gaida MM; Ogawa Y; Kolios AG; Lasitschka F; Ashwell JD
J Exp Med; 2014 Jun; 211(6):1257-70. PubMed ID: 24863062
[TBL] [Abstract][Full Text] [Related]
3. Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases.
Salvador JM; Mittelstadt PR; Guszczynski T; Copeland TD; Yamaguchi H; Appella E; Fornace AJ; Ashwell JD
Nat Immunol; 2005 Apr; 6(4):390-5. PubMed ID: 15735648
[TBL] [Abstract][Full Text] [Related]
4. TCR-independent CD30 signaling selectively induces IL-13 production via a TNF receptor-associated factor/p38 mitogen-activated protein kinase-dependent mechanism.
Harlin H; Podack E; Boothby M; Alegre ML
J Immunol; 2002 Sep; 169(5):2451-9. PubMed ID: 12193714
[TBL] [Abstract][Full Text] [Related]
5. Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses.
Garbe AI; Vermeer B; Gamrekelashvili J; von Wasielewski R; Greten FR; Westendorf AM; Buer J; Schmid RM; Manns MP; Korangy F; Greten TF
Cancer Res; 2006 Jan; 66(1):508-16. PubMed ID: 16397267
[TBL] [Abstract][Full Text] [Related]
6. The autoimmune suppressor Gadd45alpha inhibits the T cell alternative p38 activation pathway.
Salvador JM; Mittelstadt PR; Belova GI; Fornace AJ; Ashwell JD
Nat Immunol; 2005 Apr; 6(4):396-402. PubMed ID: 15735649
[TBL] [Abstract][Full Text] [Related]
7. Expansion of Tumor-reactive T Cells From Patients With Pancreatic Cancer.
Meng Q; Liu Z; Rangelova E; Poiret T; Ambati A; Rane L; Xie S; Verbeke C; Dodoo E; Del Chiaro M; Löhr M; Segersvärd R; Maeurer MJ
J Immunother; 2016; 39(2):81-9. PubMed ID: 26849077
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating IL-17-producing gammadelta T cells support the progression of tumor by promoting angiogenesis.
Wakita D; Sumida K; Iwakura Y; Nishikawa H; Ohkuri T; Chamoto K; Kitamura H; Nishimura T
Eur J Immunol; 2010 Jul; 40(7):1927-37. PubMed ID: 20397212
[TBL] [Abstract][Full Text] [Related]
9. Intra-tumoral IFN-γ-producing Th22 cells correlate with TNM staging and the worst outcomes in pancreatic cancer.
Niccolai E; Taddei A; Ricci F; Rolla S; D'Elios MM; Benagiano M; Bechi P; Bencini L; Ringressi MN; Pini A; Castiglione F; Giordano D; Satolli MA; Coratti A; Cianchi F; Bani D; Prisco D; Novelli F; Amedei A
Clin Sci (Lond); 2016 Feb; 130(4):247-58. PubMed ID: 26590104
[TBL] [Abstract][Full Text] [Related]
10. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
11. Tumor-Infiltrating B- and T-Cell Repertoire in Pancreatic Cancer Associated With Host and Tumor Features.
Pineda S; López de Maturana E; Yu K; Ravoor A; Wood I; Malats N; Sirota M
Front Immunol; 2021; 12():730746. PubMed ID: 34630409
[TBL] [Abstract][Full Text] [Related]
12. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
13. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
[TBL] [Abstract][Full Text] [Related]
14. CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma.
Chao T; Furth EE; Vonderheide RH
Cancer Immunol Res; 2016 Nov; 4(11):968-982. PubMed ID: 27737879
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Derived Myeloid Cell Chemoattractants and T Cell Exclusion in Pancreatic Cancer.
Vonderheide RH; Bear AS
Front Immunol; 2020; 11():605619. PubMed ID: 33304355
[TBL] [Abstract][Full Text] [Related]
16. Regulation of the maintenance of peripheral T-cell anergy by TAB1-mediated p38 alpha activation.
Ohkusu-Tsukada K; Tominaga N; Udono H; Yui K
Mol Cell Biol; 2004 Aug; 24(16):6957-66. PubMed ID: 15282297
[TBL] [Abstract][Full Text] [Related]
17. T cell receptor ligation triggers novel nonapoptotic cell death pathways that are Fas-independent or Fas-dependent.
Davidson WF; Haudenschild C; Kwon J; Williams MS
J Immunol; 2002 Dec; 169(11):6218-30. PubMed ID: 12444127
[TBL] [Abstract][Full Text] [Related]
18. IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production.
Yang J; Zhu H; Murphy TL; Ouyang W; Murphy KM
Nat Immunol; 2001 Feb; 2(2):157-64. PubMed ID: 11175814
[TBL] [Abstract][Full Text] [Related]
19. Tumor Cell-Intrinsic p38 MAPK Signaling Promotes IL1α-Mediated Stromal Inflammation and Therapeutic Resistance in Pancreatic Cancer.
Singh SP; Dosch AR; Mehra S; De Castro Silva I; Bianchi A; Garrido VT; Zhou Z; Adams A; Amirian H; Box EW; Sun X; Ban Y; Datta J; Nagathihalli NS; Merchant NB
Cancer Res; 2024 Apr; 84(8):1320-1332. PubMed ID: 38285896
[TBL] [Abstract][Full Text] [Related]
20. The immune network in pancreatic cancer development and progression.
Wörmann SM; Diakopoulos KN; Lesina M; Algül H
Oncogene; 2014 Jun; 33(23):2956-67. PubMed ID: 23851493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
